24/7 Market News Snapshot 06 August, 2025 – Novavax Inc (NASDAQ:NVAX)

August 6, 2025

DENVER, Colo., 06 August, 2025 (www.247marketnews.com) – (NASDAQ:NVAX) are discussed in this article.
Novavax, Inc. has recently demonstrated considerable market momentum, with its stock trading at $7.99, reflecting an 18.75% increase from the previous close of $6.73. This change signals heightened interest among investors, as indicated by a trading volume of 6.52 million shares. Key resistance levels have been surpassed, underscoring bullish momentum. Investors are advised to observe support levels at approximately $7.21, which may provide a buffer against any potential downturns in the stock’s performance.

In addition to its favorable market activity, Novavax reported strong financial results for the second quarter of 2025, achieving total revenues of $239 million. This success accompanies the FDA’s recent approval of the Biologics License Application for Nuvaxovid™, marking it as the sole recombinant protein-based, non-mRNA COVID-19 vaccine authorized in the United States. This landmark achievement has triggered a $175 million payment from Sanofi as part of a strategic partnership that will see marketing rights for U.S. and European markets transitioned later this year, positioning the company favorably for the upcoming COVID-19 vaccination season.

Moreover, Novavax is making noteworthy progress in its Phase 3 trials for both its COVID-19-Influenza Combination and standalone influenza vaccines. Preliminary results indicate strong immune responses that exceed those of the comparator arm, setting the stage for future collaborations. The company is also actively engaged in leveraging its proprietary Matrix-M adjuvant across various applications, including ongoing discussions about a malaria vaccine, which has seen over 20 million doses sold since its introduction.

For the remainder of 2025, Novavax has adjusted its financial outlook, projecting total revenue between $1 billion and $1.05 billion. This forward-looking guidance reflects the company’s focus on research and development while prioritizing fiscal responsibility as it enhances its position in the vaccine development landscape.

Related news for (NVAX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.